Natural but Not Inducible Regulatory T Cells Require TNF-α Signaling for In Vivo Function

被引:85
作者
Housley, William J. [1 ,2 ]
Adams, Catherine O. [1 ,2 ]
Nichols, Frank C. [3 ]
Puddington, Lynn [4 ]
Lingenheld, Elizabeth G. [4 ]
Zhu, Li [4 ]
Rajan, Thiruchandurai V. [5 ]
Clark, Robert B. [1 ,2 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Immunol, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT 06032 USA
[2] Univ Connecticut, Ctr Hlth, Ctr Immunotherapy Canc & Infect Dis, Dept Med, Farmington, CT 06032 USA
[3] Univ Connecticut, Ctr Hlth, Dept Oral Hlth & Diagnost Sci, Div Periodontol, Farmington, CT 06032 USA
[4] Univ Connecticut, Ctr Hlth, Ctr Integrat Immunol & Vaccine Res, Dept Immunol, Farmington, CT 06032 USA
[5] Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06032 USA
基金
美国国家卫生研究院;
关键词
TRANSCRIPTION FACTOR FOXP3; NECROSIS-FACTOR-ALPHA; TGF-BETA; CUTTING EDGE; EXPRESSION; MICE; RECEPTOR; COLITIS; AUTOIMMUNITY; LYMPHOTOXIN;
D O I
10.4049/jimmunol.1003868
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TNF-alpha has a multifunctional role in autoimmune diseases as reflected in the variable responses of different human diseases to anti-TNF-alpha therapy. Recent studies have suggested that TNF-alpha modulates autoimmunity partially via effects on regulatory T cells (Tregs) and that these effects are mediated through the type II TNFR (TNFR2). We have investigated the requirement for TNFR2-expression on murine natural Tregs (nTregs) and induced Tregs (iTregs) in mediating suppression of colitis. Surprisingly, we find that TNFR2-expression is required for both spleen- and thymus-derived nTreg-mediated suppression, but is not required for iTreg-mediated suppression. Abnormal TNFR2(-/-) nTreg function was not associated with an in vivo decrease in accumulation, stability, or expression of markers known to be relevant in Treg function. Because iTregs are generated in the presence of TGF-beta, we investigated whether activation in the presence of TGF-beta could overcome the functional defect in TNFR2(-/-) nTregs. Although preactivation alone did not restore suppressive function of nTregs, preactivation in the presence of TGF-beta did. These results identify potentially critical differences in activation requirements for nTregs versus iTregs. Furthermore, our findings are consistent with reports suggesting that nTregs are activated in sites of inflammation while iTregs are activated in lymph nodes. Finally, by demonstrating that nTregs require TNF-alpha for optimal function whereas iTregs do not, our results suggest that the enigma of variable responses of different human diseases to anti-TNF-alpha therapy may relate to whether nTregs or iTregs have the predominant regulatory role in a given disease. The Journal of Immunology, 2011, 186: 6779-6787.
引用
收藏
页码:6779 / 6787
页数:9
相关论文
共 36 条
  • [1] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study
    Arnason, BGW
    Jacobs, G
    Hanlon, M
    Clay, BH
    Noronha, ABC
    Auty, A
    Davis, B
    Nath, A
    Bouchard, JP
    Belanger, C
    Gosselin, F
    Thibault, M
    Duquette, P
    Bourgoin, P
    DuBois, R
    Girard, M
    Ebers, GC
    Rice, GPA
    Vandervoort, MK
    Francis, GS
    Duncan, L
    Lapierre, Y
    Freedman, MS
    Christie, SN
    Rabinovitch, HE
    Patry, D
    Murphy, WF
    Peters, S
    McGuiness, SD
    Murray, TJ
    Bhan, V
    Maxner, CE
    Van Dorpe, R
    Oger, JJ
    Nelson, J
    Morrison, W
    Bogle, N
    Beall, S
    Vorobeychick, G
    Hiltbrunner, AV
    Bock, J
    Habil
    Lesslauer, W
    Li, DKB
    Paty, DW
    Zhao, GJ
    [J]. NEUROLOGY, 1999, 53 (03) : 457 - 465
  • [2] Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice:: Control by CD4+ regulatory T cells and IL-10
    Asseman, C
    Read, S
    Powrie, F
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (02) : 971 - 978
  • [3] Can TNF-α boost regulatory T cells?
    Bilate, Angelina M.
    Lafaille, Juan J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (12) : 4190 - 4192
  • [4] Expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells:: Applicability to tumor-infiltrating T regulatory cells
    Chen, Xin
    Subleski, Jeffrey J.
    Kopf, Heather
    Howard, O. M. Zack
    Maennel, Daniela N.
    Oppenheim, Joost J.
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 180 (10) : 6467 - 6471
  • [5] Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells
    Chen, Xin
    Baeumel, Monika
    Maennel, Daniela N.
    Howard, O. M. Zack
    Oppenheim, Joost J.
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 179 (01) : 154 - 161
  • [6] Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood
    Chen, Xin
    Subleski, Jeffrey J.
    Hamano, Ryoko
    Howard, O. M. Zack
    Wiltrout, Robert H.
    Oppenheim, Joost J.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (04) : 1099 - 1106
  • [7] Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
    de Lafaille, Maria A. Curotto
    Lafaille, Juan J.
    [J]. IMMUNITY, 2009, 30 (05) : 626 - 635
  • [8] The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications
    De Rycke, L
    Baeten, D
    Kruithof, E
    Van den Bosch, F
    Veys, EM
    De Keyser, F
    [J]. LUPUS, 2005, 14 (12) : 931 - 937
  • [9] TNF receptor 2 pathway: drug target for autoimmune diseases
    Faustman, Denise
    Davis, Miriam
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) : 482 - 493
  • [10] Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs
    Grinberg-Bleyer, Yenkel
    Saadoun, David
    Baeyens, Audrey
    Billiard, Fabienne
    Goldstein, Jeremie D.
    Gregoire, Sylvie
    Martin, Gaelle H.
    Elhage, Rima
    Derian, Nicolas
    Carpentier, Wassila
    Marodon, Gilles
    Klatzmann, David
    Piaggio, Eliane
    Salomon, Benoit L.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (12) : 4558 - 4568